February 1, 2018 / 9:07 AM / 17 days ago

BRIEF-Roche Holding AG Drugs Chief Says Immunotherapy Competitors Taking Share From Avastin

Feb 1 (Reuters) - Roche Holding Ag:

* CFO SAYS EXPECTS HIGH THREE DIGIT MILLION TAX BENEFIT FROM U.S. TAX REFORM

* CEO SAYS U.S. TAX REFORM HAS BOOSTED U.S. COMPETITIVENESS

* DRUGS DIVISION CHIEF SAYS OCREVUS HAS 5 PERCENT MULTIPLE SCLEROSIS MARKET SHARE AFTER THREE QUARTERS OF SALES, SEES NO SLOWING IN UNITED STATES

* CEO EXPECTS OCREVUS TO “EASILY” EXCEED 1 BILLION SFR IN SALES IN 2018

* DRUGS CHIEF EXPECTS SIMILAR EROSION FOR HERCEPTIN AS RITUXAN AS BIOSIMILARS ENTER MARKET

* DRUGS CHIEF SAYS IMMUNOTHERAPY COMPETITORS TAKING MARKET SHARE FROM AVASTIN IN U.S. LUNG CANCER TREATMENT, RESULTING IN REVENUE DECLINE Source text for Eikon: Further company coverage: (Reporting by John Miller)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below